NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) have been assigned a consensus recommendation of “Moderate Buy” from the fourteen research firms that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, ten have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $49.3333.

Several equities research analysts have recently issued reports on the company. Royal Bank Of Canada lowered their price objective on NewAmsterdam Pharma from $51.00 to $50.00 and set an “outperform” rating for the company in a research note on Thursday, August 6th. BMO Capital Markets initiated coverage on shares of NewAmsterdam Pharma in a research report on Monday, July 20th. They set an “outperform” rating and a $58.00 price objective on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research note on Friday, July 17th. Wall Street Zen upgraded shares of NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $45.00 price target on shares of NewAmsterdam Pharma in a research note on Monday, July 20th.

NewAmsterdam Pharma Stock Down 0.3%

Shares of NASDAQ:NAMS opened at $26.90 on Tuesday. The firm has a fifty day simple moving average of $30.84 and a two-hundred day simple moving average of $32.26. NewAmsterdam Pharma has a 52 week low of $23.05 and a 52 week high of $42.21. The stock has a market capitalization of $3.22 billion, a P/E ratio of -12.45 and a beta of 0.10.

NewAmsterdam Pharma (NASDAQ:NAMS) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.04). The business had revenue of $3.70 million during the quarter, compared to the consensus estimate of $2.83 million. NewAmsterdam Pharma had a negative net margin of 3,644.21% and a negative return on equity of 34.81%. On average, analysts expect that NewAmsterdam Pharma will post -1.82 earnings per share for the current year.

Insider Transactions at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, CAO Louise Frederika Kooij sold 105,000 shares of the stock in a transaction on Monday, July 20th. The stock was sold at an average price of $30.34, for a total value of $3,185,700.00. Following the sale, the chief accounting officer owned 24,353 shares in the company, valued at $738,870.02. This trade represents a 81.17% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last three months, insiders sold 210,000 shares of company stock worth $6,713,550. 12.74% of the stock is owned by insiders.

Institutional Investors Weigh In On NewAmsterdam Pharma

Institutional investors have recently added to or reduced their stakes in the business. Frazier Life Sciences Management L.P. boosted its stake in NewAmsterdam Pharma by 1.4% in the 4th quarter. Frazier Life Sciences Management L.P. now owns 16,943,774 shares of the company’s stock worth $594,388,000 after purchasing an additional 241,818 shares in the last quarter. Capital World Investors increased its position in shares of NewAmsterdam Pharma by 1.6% in the 4th quarter. Capital World Investors now owns 9,984,000 shares of the company’s stock valued at $350,239,000 after acquiring an additional 161,289 shares during the period. Wellington Management Group LLP raised its stake in NewAmsterdam Pharma by 21.0% in the 3rd quarter. Wellington Management Group LLP now owns 4,020,126 shares of the company’s stock worth $114,332,000 after acquiring an additional 697,129 shares during the last quarter. Adage Capital Partners GP L.L.C. lifted its position in NewAmsterdam Pharma by 54.5% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 3,013,009 shares of the company’s stock worth $54,566,000 after acquiring an additional 1,062,359 shares during the period. Finally, Polar Capital Holdings Plc grew its stake in NewAmsterdam Pharma by 15.6% during the 3rd quarter. Polar Capital Holdings Plc now owns 2,911,634 shares of the company’s stock valued at $82,807,000 after purchasing an additional 393,855 shares during the last quarter. Institutional investors and hedge funds own 89.89% of the company’s stock.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.